Barber Daniel sold $100K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at an average of $4.01 ($4.00–$4.03, $0.10M total) across 2 trades over 2026-07-15 to 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Jul 17, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 5:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
high confidence
Mentioned
$AQST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not introduce new company fundamentals. The 10b5-1 plan reduces interpretability as a forward-looking negative signal.

02

Market read

Primarily a sentiment/positioning datapoint for AQST, with limited expected impact absent other catalysts.

03

What to watch

Traders may over-weight the optics of insider selling; without accompanying changes in guidance, trials, or financing, the signal is likely weak.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-17, covering sales executed 2026-07-15 to 2026-07-16.

Background

The article is an SEC Form 4 insider transaction for Aquestive Therapeutics, Inc. (AQST) by its President and CEO.

Company-level read

Ticker impact

$AQSTNeutralHigh confidence
Context

Aquestive Therapeutics CEO Barber Daniel sold about $100.2K of AQST shares in two open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and the article provides no new operational, regulatory, or financial catalyst.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • AQST

    Aquestive Therapeutics, Inc., issuer of the Form 4 insider sale.

  • Barber Daniel

    President and CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.